Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	3.27B
Revenue (ttm)	749.00M
Net Income (ttm)	132.27M
Shares Out	51.15M
EPS (ttm)	2.59
PE Ratio	24.71
Forward PE	21.91
Dividend	0.94 (1.46%)
Ex-Dividend Date	Jul 14, 2025

Volume	153,412
Average Volume	140,716
Open	64.05
Previous Close	63.95
Day's Range	62.85 - 64.85
52-Week Range	45.52 - 80.20
Beta	0.50
RSI	67.06
Earnings Date	Nov 6, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.